420 related articles for article (PubMed ID: 11554173)
1. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
Huh YO; Keating MJ; Saffer HL; Jilani I; Lerner S; Albitar M
Am J Clin Pathol; 2001 Sep; 116(3):437-43. PubMed ID: 11554173
[TBL] [Abstract][Full Text] [Related]
2. [Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases].
Suková V; Klabusay M; Coupek P; Brychtová Y; Doubek M; Mayer J
Cas Lek Cesk; 2006; 145(9):712-6; discussion 716-7. PubMed ID: 17091727
[TBL] [Abstract][Full Text] [Related]
3. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of marginal zone lymphoma involving bone marrow.
Kent SA; Variakojis D; Peterson LC
Am J Clin Pathol; 2002 May; 117(5):698-708. PubMed ID: 12090417
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
6. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
Tam CS; Otero-Palacios J; Abruzzo LV; Jorgensen JL; Ferrajoli A; Wierda WG; Lerner S; O'Brien S; Keating MJ
Br J Haematol; 2008 Apr; 141(1):36-40. PubMed ID: 18324964
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.
Wang L; Abbasi F; Gaigalas AK; Vogt RF; Marti GE
Cytometry B Clin Cytom; 2006 Nov; 70(6):410-5. PubMed ID: 16967494
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples.
Xu Y; McKenna RW; Asplund SL; Kroft SH
Am J Clin Pathol; 2002 Nov; 118(5):758-64. PubMed ID: 12428797
[TBL] [Abstract][Full Text] [Related]
10. Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia.
Rossmann ED; Lenkei R; Lundin J; Mellstedt H; Osterborg A
Cytometry B Clin Cytom; 2007 Nov; 72(6):450-7. PubMed ID: 17565749
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis.
Molica S; Mannella A; Dattilo A; Levato D; Iuliano F; Peta A; Consarino C; Magro S
Haematologica; 1996; 81(4):302-9. PubMed ID: 8870373
[TBL] [Abstract][Full Text] [Related]
12. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
13. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
[TBL] [Abstract][Full Text] [Related]
14. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes.
Yağci M; Akar I; Sucak GT; Haznedar R
Leuk Res; 2005 Jul; 29(7):735-8. PubMed ID: 15927668
[TBL] [Abstract][Full Text] [Related]
16. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
17. Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia.
Bojarska-Junak A; Rolinski J; Wasik-Szczepaneko E; Kaluzny Z; Dmoszynska A
Haematologica; 2002 May; 87(5):490-9. PubMed ID: 12010662
[TBL] [Abstract][Full Text] [Related]
18. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
Chu PG; Loera S; Huang Q; Weiss LM
Am J Clin Pathol; 2006 Oct; 126(4):534-44. PubMed ID: 16938666
[TBL] [Abstract][Full Text] [Related]
19. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow.
Hartmann TN; Grabovsky V; Wang W; Desch P; Rubenzer G; Wollner S; Binsky I; Vallon-Eberhard A; Sapoznikov A; Burger M; Shachar I; Haran M; Honczarenko M; Greil R; Alon R
Cancer Res; 2009 Apr; 69(7):3121-30. PubMed ID: 19293181
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).
Sokol L; Agosti SJ
Am J Hematol; 2004 Feb; 75(2):107-9. PubMed ID: 14755378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]